2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163382
    Cbz-Gly-Pro-Ala-O-cinnamyl 98%
    Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC50 values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease.
    Cbz-Gly-Pro-Ala-O-cinnamyl
  • HY-163394
    CB2 receptor agonist 6 98%
    CB2 receptor agonist 6 (compound 70) is an agonist of CB2R, with EC50 of 162 nM. The IC50 values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for CB2R. CB2 receptor agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease.
    CB2 receptor agonist 6
  • HY-163415
    MAO-IN-5 906728-07-2 98%
    MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases.
    MAO-IN-5
  • HY-163441
    BChE-IN-31 98%
    BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC50 of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide.
    BChE-IN-31
  • HY-163455
    pan-HCN-IN-1 1334308-63-2 98%
    pan-HCN-IN-1 (Compound J&J12e) is an inhibitor for hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channel, with IC50 of 58 nM. pan-HCN-IN-1 reduces the voltage sag response and enhances EPSP summation in ex vivo rats brain slices.
    pan-HCN-IN-1
  • HY-163465
    DTNP 3010266-66-4 98%
    DTNP is a BchE -activated near infrared (NIR) probe with blood-brain permeability. DTNP can be activated by BchE and inhibit its enzyme activity. DTNP can be used in Alzheimer's disease (AD) research.
    DTNP
  • HY-163474
    MAO-B-IN-32 98%
    MAO-B-IN-32 is an inhibitor of MAO-B (IC50 = 16 nM).MAO-B-IN-32 increases dopamine concentration in the brain by inhibiting MAO-B activity.
    MAO-B-IN-32
  • HY-163497
    NLRP3-IN-38 3033054-46-2 98%
    NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM.
    NLRP3-IN-38
  • HY-163498
    NLRP3-IN-37 3033054-51-9 98%
    NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
    NLRP3-IN-37
  • HY-163514
    hAChE-IN-8 98%
    hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research.
    hAChE-IN-8
  • HY-163519
    α-Synuclein inhibitor 13 98%
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research.
    α-Synuclein inhibitor 13
  • HY-163537
    AChE/BuChE-IN-5 98%
    AChE/BuChE-IN-5 (compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE) (IC50=46.9 nM) and butyryl cholinesterase (BuChE) (IC50=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research.
    AChE/BuChE-IN-5
  • HY-163543
    Progranulin modulator-2 98%
    Progranulin modulator-2 (compound 18A) is a bromodomain and extra-terminal domain (BET) inhibitor. Progranulin modulator-2 enhances PGRN expression by targeting members of the BET protein family. Progranulin modulator-2 can be used to study the role of BET protein in neurodevelopment, neuroplasticity and neurodegeneration.
    Progranulin modulator-2
  • HY-163564
    JYQ-194 98%
    JYQ-194 is a PROTAC degrader targeting human Parkinson's disease protein 7 (PARK7). JYQ-194 can be used in the study of cancer and neurodegenerative diseases. (Pink: PARK7 ligand (HY-163563); Black: linker (HY-W017440); Blue: E3 ligase ligand (HY-10984)).
    JYQ-194
  • HY-163574
    TDP-43-IN-1 3033951-71-9 98%
    TDP43-IN-1 (example 8) is a TDP43 inhibitor, and can be used for study of neurodegenerative disorders.
    TDP-43-IN-1
  • HY-163575
    TDP-43-IN-2 3033951-93-5 98%
    TDP-43-IN-2 (compound 17) is a TDP-43 inhibitor, and can be used for study of neurodegenerative disease.
    TDP-43-IN-2
  • HY-163613
    NS163 98%
    NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.
    NS163
  • HY-163646
    (Rac)-TZ3O 2218754-19-7 98%
    (Rac)-TZ3O is the (Rac) isomer of TZ3O. TZ3O is an anticholinergic compound with neuroprotective activity. TZ3O improves memory impairment and cognitive decline in a scopolamine-induced Alzheimer's disease rat model and can be used in the study of Alzheimer's disease.
    (Rac)-TZ3O
  • HY-163655
    Glutaminyl Cyclase Inhibitor 6 98%
    Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cyclase (gQC) inhibitor with IC50 values of 0.012 0.040 µM, respectively. Glutaminyl Cyclase Inhibitor 6 has the potential for the research of Parkinson’s disease.
    Glutaminyl Cyclase Inhibitor 6
  • HY-163667
    Atoxifent 98%
    Atoxifent is a potent μ-opioid receptor agonist (EC50=0.39 nM). These receptors are found in brain regions that control pain, emotions, habitual learning, and cognition. Atoxifent exhibits strong analgesic effects and a lower risk of respiratory depression. Atoxifent can be used for research in opioid pharmacology and signal transduction.
    Atoxifent
Cat. No. Product Name / Synonyms Application Reactivity